Pfiz­er's Paxlovid on­ly helped se­niors avoid hos­pi­tal­iza­tion and death, new NE­JM study finds

Us­age of Pfiz­er’s Covid-19 treat­ment Paxlovid has spiked across the US in re­cent months, with more than 2 mil­lion cours­es ad­min­is­tered dur­ing this lat­est Omi­cron wave since June, po­ten­tial­ly sav­ing many from hos­pi­tal­iza­tion or death.

But a new ob­ser­va­tion­al study pub­lished in the New Eng­land Jour­nal of Med­i­cine on Wednes­day evening found that Paxlovid on­ly worked among pa­tients 65 years of age or old­er, with no ev­i­dence of ben­e­fit found in younger adults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA